insights_auto
Por que 8NE caiu 4,69%?
Saiba maischevron_right
8NE:FRA
Lisata Therapeutics, Inc.
€ 0,92
arrow_downward
-4,69%(-0,045) 1D
8 de out., 08:03:01 GMT+2 · EUR
search
Todos os ativos
| Códigos | Preço | Variação | % de variação |
|---|
insights_autoGerando os principais insights para 8NE…
Abrir
€ 0,92
Alta
€ 0,92
Baixa
€ 0,92
Valor de mercado
12,86 mi
Volume médio
0,00
Volume
0,00
Alto — 52 sem
€ 4,34
Baixo — 52 sem
€ 0,74
Nº de funcionários
21
Abrir
€ 0,92
Alta
€ 0,92
Baixa
€ 0,92
Valor de mercado
12,86 mi
Volume médio
0,00
Volume
0,00
Alto — 52 sem
€ 4,34
Baixo — 52 sem
€ 0,74
Nº de funcionários
21
Notícias
De fontes da web e parceiros de notícias
Yahoo Finance
·
há 2 horas
Lisata Therapeutics wins new US patent for pancreatic cancer drug
Investing.com
·
há 3 horas
Lisata Therapeutics receives patent for certepetide cancer treatment
Stock Titan
·
há 3 horas
A new cancer-treatment patent adds market exclusivity into 2043, Lisata says.
Investing.com UK
·
há 18 horas
Form PRE 14A Lisata Therapeutics For: 7 October By Investing.com
Perfil
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
Sobre Lisata Therapeutics, Inc.
CEO-
Funcionários21
Data de fundação1980
SedeBasking Ridge, Nova Jersey, Estados Unidos
Setor-
Sitelisata.com